secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001213900-24-098530
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka files retroactively adjusted pre-merger audited financials as of Feb 6, 2024
--------------------------------------------------------------------------------

- Balance sheet shows $1K subscription receivable, zero cash; total stockholders' equity $1K.
- Auditor's report includes going concern qualification due to no revenue and operating losses.
- Adjustments reflect 1-for-12 reverse stock split and 6.8569 exchange ratio from August 2024 merger.
- No new operational or financial information beyond the previously closed business combination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390024098530/0001213900-24-098530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390024098530/ea0221362-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-098530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer